MXPA04005420A - Composicion farmaceutica que comprende un agonista de receptor de 5ht1. - Google Patents
Composicion farmaceutica que comprende un agonista de receptor de 5ht1.Info
- Publication number
- MXPA04005420A MXPA04005420A MXPA04005420A MXPA04005420A MXPA04005420A MX PA04005420 A MXPA04005420 A MX PA04005420A MX PA04005420 A MXPA04005420 A MX PA04005420A MX PA04005420 A MXPA04005420 A MX PA04005420A MX PA04005420 A MXPA04005420 A MX PA04005420A
- Authority
- MX
- Mexico
- Prior art keywords
- receptor agonist
- pharmaceutical composition
- composition
- swallowed
- dispersion
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0007—Effervescent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Abstract
La presente invencion se refiere a una composicion farmaceutica para administracion oral capaz desintegrarse y dispersarse rapidamente dentro del tracto gastrointestinal que comprende un agonista de receptor de 5HT1 como ingrediente activo, en particular una composicion en forma de dosis solida que esta disenada para ser deglutida, y metodos de tratamiento de dolor cefalico, especialmente migrana, usando dicha composicion.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0129117.8A GB0129117D0 (en) | 2001-12-05 | 2001-12-05 | Pharmaceutical composition |
PCT/EP2002/013715 WO2003047552A2 (en) | 2001-12-05 | 2002-12-04 | Pharmaceutical composition comprising a 5ht1 receptor agonist |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA04005420A true MXPA04005420A (es) | 2004-10-11 |
Family
ID=9927051
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA04005420A MXPA04005420A (es) | 2001-12-05 | 2002-12-04 | Composicion farmaceutica que comprende un agonista de receptor de 5ht1. |
Country Status (29)
Country | Link |
---|---|
US (1) | US20050032867A1 (es) |
EP (2) | EP1450770B1 (es) |
JP (1) | JP3699969B2 (es) |
KR (1) | KR100591237B1 (es) |
CN (1) | CN1289069C (es) |
AR (1) | AR037627A1 (es) |
AT (1) | ATE291900T1 (es) |
AU (1) | AU2002358602B2 (es) |
BR (1) | BR0214497A (es) |
CA (1) | CA2469019C (es) |
CO (1) | CO5580741A2 (es) |
DE (1) | DE60203537T2 (es) |
ES (1) | ES2236608T3 (es) |
FI (1) | FI20022128A (es) |
GB (1) | GB0129117D0 (es) |
HK (1) | HK1069111A1 (es) |
HU (1) | HU229313B1 (es) |
IL (1) | IL161997A (es) |
IS (1) | IS2481B (es) |
MX (1) | MXPA04005420A (es) |
MY (1) | MY129314A (es) |
NO (1) | NO329896B1 (es) |
NZ (1) | NZ532829A (es) |
PL (1) | PL194702B1 (es) |
PT (1) | PT1450770E (es) |
RU (1) | RU2285526C2 (es) |
TW (1) | TWI240638B (es) |
WO (1) | WO2003047552A2 (es) |
ZA (1) | ZA200403849B (es) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8071128B2 (en) | 1996-06-14 | 2011-12-06 | Kyowa Hakko Kirin Co., Ltd. | Intrabuccally rapidly disintegrating tablet and a production method of the tablets |
US9358214B2 (en) | 2001-10-04 | 2016-06-07 | Adare Pharmaceuticals, Inc. | Timed, sustained release systems for propranolol |
US8367111B2 (en) | 2002-12-31 | 2013-02-05 | Aptalis Pharmatech, Inc. | Extended release dosage forms of propranolol hydrochloride |
WO2004089365A1 (en) | 2003-04-11 | 2004-10-21 | Pfizer Limited | Pharmaceutical combination comprising eletriptan and sodium bicarbonate |
AU2004247076A1 (en) * | 2003-06-06 | 2004-12-23 | Glaxo Group Limited | Composition comprising triptans and NSAIDs |
ES2624585T3 (es) * | 2004-05-28 | 2017-07-17 | Imaginot Pty Ltd. | Sistema de suministro de compuesto terapéutico oral |
US8216610B2 (en) * | 2004-05-28 | 2012-07-10 | Imaginot Pty Ltd. | Oral paracetamol formulations |
US8747895B2 (en) | 2004-09-13 | 2014-06-10 | Aptalis Pharmatech, Inc. | Orally disintegrating tablets of atomoxetine |
US9884014B2 (en) | 2004-10-12 | 2018-02-06 | Adare Pharmaceuticals, Inc. | Taste-masked pharmaceutical compositions |
WO2006047493A2 (en) | 2004-10-21 | 2006-05-04 | Eurand Pharmaceuticals Limited | Taste-masked pharmaceutical compositions with gastrosoluble pore-formers |
US9161918B2 (en) | 2005-05-02 | 2015-10-20 | Adare Pharmaceuticals, Inc. | Timed, pulsatile release systems |
EP3449928A1 (en) * | 2005-11-28 | 2019-03-06 | Imaginot Pty Ltd. | Oral therapeutic compound delivery system |
CN101431895A (zh) * | 2006-05-01 | 2009-05-13 | 卡普里康制药公司 | 新颖的曲坦制剂和制备它们的方法 |
WO2008039358A2 (en) * | 2006-09-30 | 2008-04-03 | Capricorn Pharma Inc. | Resin-complex granulation for water-soluble drugs and associated methods |
KR101765357B1 (ko) | 2009-12-02 | 2017-08-04 | 아데어 파마수티컬스 에스.알.엘. | 펙소페나딘 마이크로캡슐 및 그것을 함유하는 조성물 |
US11364225B2 (en) | 2019-08-21 | 2022-06-21 | Bn Intellectual Properties, Inc. | Pharmaceutical formulation for treating symptoms of migraine and cluster headaches, and method of using the same |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9027827D0 (en) * | 1990-12-21 | 1991-02-13 | Glaxo Laboratoires | Pharmaceutical compositions |
US5468504A (en) * | 1990-12-21 | 1995-11-21 | Laboratoires Glaxo S.A. | Effervescent pharmaceutical compositions |
GB9104890D0 (en) * | 1991-03-08 | 1991-04-24 | Glaxo Group Ltd | Compositions |
US5460972A (en) * | 1991-04-08 | 1995-10-24 | Research Foundation Of The State University Of New York | Ionized magnesium2+ concentrations in biological samples |
US6649186B1 (en) * | 1996-09-20 | 2003-11-18 | Ethypharm | Effervescent granules and methods for their preparation |
GB9704524D0 (en) * | 1997-03-05 | 1997-04-23 | Smithkline Beecham Plc | Composition |
GB9706089D0 (en) * | 1997-03-24 | 1997-05-14 | Scherer Ltd R P | Pharmaceutical composition |
AU2640599A (en) * | 1998-02-26 | 1999-09-15 | Banyu Pharmaceutical Co., Ltd. | An orally disintegrating composition and its manufacturing method |
US6350470B1 (en) * | 1998-04-29 | 2002-02-26 | Cima Labs Inc. | Effervescent drug delivery system for oral administration |
US6383471B1 (en) * | 1999-04-06 | 2002-05-07 | Lipocine, Inc. | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
US6264981B1 (en) * | 1999-10-27 | 2001-07-24 | Anesta Corporation | Oral transmucosal drug dosage using solid solution |
EP1246668B1 (en) * | 1999-12-01 | 2005-11-30 | Natco Pharma Limited | An rapid acting freeze dired oral pharmaceutical composition for treating migraine |
US20020001617A1 (en) * | 2000-05-26 | 2002-01-03 | Chang-Hyun Lee | Rapidly disintegrating tablet and process for the manufacture thereof |
US20030008005A1 (en) * | 2001-07-05 | 2003-01-09 | R.T. Alamo Ventures, Inc. | Sublingual administration of dihydroergotamine for the treatment of migraine |
-
2001
- 2001-12-05 GB GBGB0129117.8A patent/GB0129117D0/en not_active Ceased
-
2002
- 2002-12-03 AR ARP020104674A patent/AR037627A1/es unknown
- 2002-12-03 TW TW091134979A patent/TWI240638B/zh not_active IP Right Cessation
- 2002-12-03 MY MYPI20024534A patent/MY129314A/en unknown
- 2002-12-03 FI FI20022128A patent/FI20022128A/fi not_active Application Discontinuation
- 2002-12-03 NO NO20025805A patent/NO329896B1/no not_active IP Right Cessation
- 2002-12-04 PT PT02792887T patent/PT1450770E/pt unknown
- 2002-12-04 IL IL16199702A patent/IL161997A/xx active IP Right Grant
- 2002-12-04 ES ES02792887T patent/ES2236608T3/es not_active Expired - Lifetime
- 2002-12-04 MX MXPA04005420A patent/MXPA04005420A/es active IP Right Grant
- 2002-12-04 RU RU2004120292/15A patent/RU2285526C2/ru not_active IP Right Cessation
- 2002-12-04 PL PL02370669A patent/PL194702B1/pl unknown
- 2002-12-04 AT AT02792887T patent/ATE291900T1/de active
- 2002-12-04 AU AU2002358602A patent/AU2002358602B2/en not_active Expired
- 2002-12-04 US US10/497,749 patent/US20050032867A1/en not_active Abandoned
- 2002-12-04 EP EP02792887A patent/EP1450770B1/en not_active Expired - Lifetime
- 2002-12-04 NZ NZ532829A patent/NZ532829A/en not_active IP Right Cessation
- 2002-12-04 HU HU0402178A patent/HU229313B1/hu unknown
- 2002-12-04 WO PCT/EP2002/013715 patent/WO2003047552A2/en active IP Right Grant
- 2002-12-04 EP EP05075288A patent/EP1527773A1/en not_active Withdrawn
- 2002-12-04 KR KR1020047008687A patent/KR100591237B1/ko active IP Right Grant
- 2002-12-04 CA CA002469019A patent/CA2469019C/en not_active Expired - Lifetime
- 2002-12-04 JP JP2003548808A patent/JP3699969B2/ja not_active Expired - Lifetime
- 2002-12-04 DE DE60203537T patent/DE60203537T2/de not_active Expired - Lifetime
- 2002-12-04 CN CNB028244184A patent/CN1289069C/zh not_active Expired - Fee Related
- 2002-12-04 BR BR0214497-2A patent/BR0214497A/pt not_active Application Discontinuation
-
2004
- 2004-05-19 ZA ZA2004/03849A patent/ZA200403849B/en unknown
- 2004-06-03 IS IS7293A patent/IS2481B/is unknown
- 2004-06-03 CO CO04052110A patent/CO5580741A2/es active IP Right Grant
-
2005
- 2005-02-28 HK HK05101699A patent/HK1069111A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MXPA04005420A (es) | Composicion farmaceutica que comprende un agonista de receptor de 5ht1. | |
TW200633730A (en) | Oral disintegrating dosage forms | |
PL367277A1 (en) | Methods of making sustained release formulations of oxymorphone related applications | |
NO993520D0 (no) | Doseringsformer og fremgangsmåte for å bedre erektil dysfunksjon | |
EP2248519A3 (en) | Non-mucoadhesive film dosage forms | |
MY133423A (en) | Pharmaceutical combinations and their use in treating gastrointestinal disorders | |
UA90858C2 (ru) | Композиция с контролируемым высвобождением варденафила | |
IL165279A (en) | Use of alpha-adrenergic agonists and alpha-2a antagonists for the preparation of pharmaceutical compositions for alleviating pain | |
HUP0401195A2 (hu) | Averziót okozó szert tartalmazó készítmények opioidokkal való visszaélés megakadályozására | |
BG66093B1 (bg) | Състави с контролирано освобождаване, съдържащи нимесулид | |
MY144897A (en) | 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists | |
MX2007005238A (es) | Una composicion veterinaria transmucosal que comprende detomidina. | |
MXPA05008838A (es) | Formulaciones de absorcion acelerada del agonista selectivo de la 5-ht. | |
EP1993567A4 (en) | PER OS ADMINISTRABLE GALLIUM PREPARATIONS AND METHODS OF USE | |
WO2006072940A3 (en) | Controlled long acting release pharmaceutical preparation for use in the oral cavity | |
MX2007006635A (es) | Formulacion farmaceutica de inhibidores dela carboxamida vih integrasa que contienen una composicion que controla la velocidad de liberacion. | |
NZ605469A (en) | Nalbuphine-based formulations and uses thereof | |
IL158668A0 (en) | Deuterated 3-piperidinopropiophenone and medicaments containing said compounds | |
PL370529A1 (en) | Use of 2-oxo-1-pyrrolidine derivatives for the preparation of a drug | |
NZ514129A (en) | Tolperison-containing, pharmaceutical preparation for oral administration | |
WO2002011694A3 (en) | COMPOSITIONS AND DOSAGE FORMS FOR APPLICATION IN ORAL CAVITY IN THE TREATMENT OF MYCOSIS | |
MXPA06000332A (es) | Nueva composicion farmaceutica solida que comprende amisulprida. | |
AP1485A (en) | Orally administered controlled delivery system for once daily administration of ciprofloxacin. | |
HUP0203148A2 (hu) | Mirtazapint tartalmazó orálisan dezintegrálódó készítmény | |
AU2001246388A1 (en) | Controlled release pharmaceutical composition containing midodrine and/or desglymidodrine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |